CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

March 31, 2025

By Krish Patel, MD
Saurabh Dahiya, MD, FACP

Opinion

Video

Panelists discuss that when selecting a chimeric antigen receptor T-cell (CAR T) product for a patient with an aggressive clinical course and eligibility for cellular therapy, key considerations include urgency, toxicity risks, and efficacy. Factors such as time to manufacture, cytokine release syndrome/immune effector cell–associated neurotoxicity syndrome rates, long-term remission data, and antigen specificity guide decision-making.

EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy

EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL

EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL

EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL

EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management

EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection

EP: 7.Personalizing CAR T: Making the Right Call for Each Patient

EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL

EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?

Now Viewing

EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care

Video content above is prompted by the following:

Given the aggressive clinical course and patient eligibility for cellular therapy and considering the urgency, toxicity risks, and efficacy profiles, what factors would guide your choice between available CAR T products?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!